EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Read related BMJ news item
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riggs, G.
Right arrow Articles by Holloway, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Riggs, G.
Right arrow Articles by Holloway, R.
Evidence-Based Medicine 2004; 9:148
© 2004 BMJ Publishing Group Ltd.

Therapeutics

Rofecoxib did not slow progression of dementia in patients with established Alzheimer’s disease

Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66–71.[Abstract/Free Full Text]

Q In patients with established Alzheimer’s disease (AD), does rofecoxib slow progression of dementia?

Clinical impact ratings Neurology *****{star}{star} Geriatrics *******

Key Words: Alzheimer’s disease • anti-inflammatory agents (non-steroidal) • cyclooxygenase inhibitors • lactones

The first 150 words of the full text of this article appear below.

METHODS
{ebmflochart.f1}Design: randomised controlled trial.

{ebmclsdenvelop.f1}Allocation: {concealed*}.{dagger}

{ebmhalfeye.f1}Blinding: blinded {patients, clinicians, data collectors, outcome assessors, and data analysts}{dagger}.*

{ebmhourglass.f1}Follow up period: 12 months.

{ebmglobe.f1}Setting: 31 sites in the US.

{ebmpatient.f1}Patients: 692 patients who were >=50 years of age (mean age 76 y, 53% women), met standard research criteria for possible or probable AD, had mild or moderate dementia (Mini-Mental State Examination [MMSE] score 14–26 and a Clinical Dementia Rating [CDR] global score no worse than moderate dementia), and had a reliable informant or caregiver to accompany them to clinic visits and ensure that they took the test medication. Exclusion criteria: history of angina or congestive heart failure with symptoms at rest; uncontrolled hypertension; myocardial infarction, coronary artery bypass, angioplasty, or stent replacement in the previous year; stroke, multiple lacunar infarcts, or transient ischaemic events in the previous 2 years; gastrointestinal bleeding in the previous 3 months; and long term . . . [Full text of this article]

Garrett Riggs, MD, PhD, Robert Holloway, MD, MPH

University of Rochester Medical Center
Rochester, New York, USA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.